Key Aspects of Managing Early Phase Development Programs For Long Term Success

BioProcess International

Home | Downstream | Upstream | Manufacturing | Archive

Webcast Information

Key Aspects of Managing Early Phase Development Programs For Long Term Success

From selection of a cell line to release of the first clinical batch, product and process developers make decisions that have timeline, financial, and regulatory consequences. As contract manufacturing becomes the norm rather than the exception in our industry, it is important that a Sponsor and CMO make the best use of each other's expertise for maximum benefit to product and patients. In this presentation, Dr. George Koch, Chief Scientific Officer for Contract Manufacturing and Director of Project Management with Fujifilm Diosynth Biotechnologies, provides insight into:

Selecting a CMO
Process and Method Development
The First Tox Lots
The First Clinical Lots

View this on-demand educational webcast to learn more about manufacturing best practices for preclinical activities.

Targeted BPI Content

Disposable Downstream Processing for Clinical Manufacturing
BioProcess International, May 2011
Read more.

Maintaining Product Titer While Replacing Undefined Components in a CHO Culture System
BioProcess International, September 2009
Read more.

Practical Considerations for DoE Implementation in Quality By Design
BioProcess International, June 2010
Read more.

Raw Material Control Strategies for Bioprocesses
BioProcess International, September 2009
Read more.

Changes in Raw Material Sources from Suppliers
BioProcess International, April 2010
Read more.

Measuring Manufacturing Cost and Its Impact on Organizations
BioProcess International, June 2010
Read more.